Central Composite Design for Optimization of Mitomycin C-Loaded Quantum Dots/Chitosan Nanoparticles as Drug

Fariza Aina Abd Manan1, Nor Azah Yusof1,2, Jaafar Abdullah1,2

  • 1Institute of Nanoscience and Nanotechnology, Universiti Putra Malaysia, UPM Serdang, Serdang 43400, Selangor, Malaysia.

Pharmaceutics
|January 21, 2023
PubMed

Insights

This study optimized a novel nanocarrier system for delivering Mitomycin C (MMC) chemotherapy. The developed MMC-loaded chitosan nanocarrier conjugated with quantum dots shows potential for effective cancer treatment.

Area of Science:

  • Nanotechnology and Drug Delivery
  • Materials Science
  • Oncology

Background:

  • Cancer remains a leading cause of mortality worldwide, necessitating advanced therapeutic strategies.
  • Drug nanocarrier systems offer a promising approach for targeted and effective delivery of anticancer agents.
  • Chitosan nanocarriers conjugated with quantum dots provide a platform for enhanced drug loading and bioimaging.

Purpose of the Study:

  • To optimize an anticancer drug formulation using Mitomycin C (MMC) encapsulated in chitosan nanocarriers conjugated with Mn:ZnS quantum dots (MMC@CS-Mn:ZnS).
  • To evaluate the encapsulation efficiency and drug release kinetics of the optimized nanocarrier system.
  • To assess the potential of the developed nanocarrier for treating non-muscle invasive bladder cancer.

Main Methods:

  • Response Surface Methodology (RSM) with a Central Composite Design (CCD) was employed to optimize encapsulation efficiency.
  • Encapsulation efficiency was determined using UV-Vis spectroscopy.
  • Physicochemical characterization was performed using nanosizer and field-emission scanning electron microscopy (FESEM). Drug release studies were conducted at various pH levels, and kinetic models (Korsmeyer-Peppas) were applied.

Main Results:

  • The highest encapsulation efficiency (EE%) of 55.31 ± 3.09% was achieved under optimized conditions (incubation time: 105 min, MMC concentration: 0.875 mg/mL, nanocarrier concentration: 5.0 mg/mL).
  • The nanocarrier system exhibited pH-dependent drug release, with the highest cumulative release (81.44%) observed at pH 5.5.
  • The Korsmeyer-Peppas model best described the drug release kinetics, indicating a diffusion-controlled release mechanism.

Conclusions:

  • The synthesized MMC@CS-Mn:ZnS nanocarrier system demonstrates efficient drug loading and controlled release capabilities.
  • The pH-responsive drug release profile suggests potential for targeted delivery in acidic tumor microenvironments.
  • This optimized nanocarrier holds promise for the simultaneous treatment of recurrence and progression in non-muscle invasive bladder cancer.